N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(4-ethoxyphenyl)-6,7-dimethoxy-1-oxo-1,2-dihydroisoquinoline-4-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(4-ethoxyphenyl)-6,7-dimethoxy-1-oxo-1,2-dihydroisoquinoline-4-carboxamide
• 英文别名: N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4-ethoxyphenyl)-6,7-dimethoxy-1-oxoisoquinoline-4-carboxamide
• 化学式: C₂₈H₂₆N₂O₇
• mdl: MFCD14717812
• 分子量: 502.5
• InChiKey: GBGIIYKTYLNMKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  95.6
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• TAF1 inhibitors for the therapy of cancer
  申请人：CeMM—Forschungszentrum für Molekulare Medizin GmbH

  公开号：US10702518B2

  公开（公告）日：2020-07-07

  The present invention relates to lactam derivatives of formula (I) for use as medicaments as well as pharmaceutical compositions comprising these compounds, particularly for use as inhibitors of the bromodomain-containing protein TAF1 (i.e., transcription initiation factor TFIID subunit 1) and for use in the treatment or prevention of cancer.

  本发明涉及用作药物的式(I)内酰胺衍生物以及包含这些化合物的药物组合物，特别是用作含溴结构域蛋白 TAF1（即转录起始因子 TFIID 亚基 1）的抑制剂以及用于治疗或预防癌症。
• TAF1 INHIBITORS FOR THE THERAPY OF CANCER
  申请人：CeMM - Forschungszentrum für Molekulare Medizin GmbH

  公开号：US20190117641A1

  公开（公告）日：2019-04-25

  The present invention relates to lactam derivatives of formula (I) for use as medicaments as well as pharmaceutical compositions comprising these compounds, particularly for use as inhibitors of the bromodomain-containing protein TAF1 (i.e., transcription initiation factor TFIID subunit 1) and for use in the treatment or prevention of cancer.